Flora Tzifi

Dr. Flora Tzifi


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2014 in Endocrine, Metabolic & Immune Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
FTFlora Tzifi
Flora Tzifi
VGVasilis Grammeniatis
Vasilis Grammeniatis
MPMarios Papadopoulos
Marios Papadopoulos
Abstract: Soy milk formula has limited medical indications for infants feeding, although in several parts of the world it has been used as a source of nutrition in a large number of children. It used to be the main alternative feeding for infants allergic to cow’s milk who did not breastfeed before the introduction of extensively hydrolyzed formulas. Although there is a debate, the fact that some children are allergic to soy or some children with cow’s milk allergy can present with concomitant soy allergy, restricted the use of soy formulas for treatment of infants allergic to cow’s milk. Other grainbased formulas like the rice-based ones are promising in infants with cow’s milk allergy. Grain-based formulas could be an alternative and cheaper way of nutrition for infants allergic to cow’s milk than extensively hydrolyzed formulas. Further large scale longitudinal clinical studies are required to clarify the safety of soy and other grain-based formulas for treatment of cow’s milk allergy.

3 August 2013 in BMC Immunology
Verified
Journal Article
Open access
PDF file
FTFlora Tzifi
Flora Tzifi
MKMaria Kanariou
Maria Kanariou
MTMarianna Tzanoudaki
Marianna Tzanoudaki
CMConstantinos Mihas
Constantinos Mihas
EPEvangelia Paschali
Evangelia Paschali
CKChristina Kanaka-Gantenbein
Christina Kanaka-Gantenbein
Data regarding the quantitative expression of TCR Vβ subpopulations in children with autoimmune diseases provided interesting and sometimes conflicting results. The aim of the present study was to assess by comparative flow cytometric analysis the peripheral blood CD4+ TCR Vβ repertoire of children with an organ-specific autoimmune disorder, such as type 1 diabetes mellitus (T1DM), in comparison to children with a systemic autoimmune disease, such as Systemic Lupus Erythematosus (SLE) in comparison to healthy age-matched controls of the same ethnic origin. The CD4+ TCR Vβ repertoire was analysed by flow cytometry in three groups of participants: a) fifteen newly diagnosed children with T1DM (mean age: 9.2 ± 4.78 years old), b) nine newly diagnosed children with SLE, positive for ANA and anti-dsDNA, prior to treatment (mean age: 12.8 ±1.76 years old) and c) 31 healthy age-matched controls (mean age: 6.58 ± 3.65 years old), all of Hellenic origin.

28 May 2019 in Hormones
Verified
Journal Article
Closed access
PDF file
FTFlora Tzifi
Flora Tzifi
AFAndreas Fretzayas
Andreas Fretzayas
GCGeorge Chrousos
George Chrousos
CKChristina Kanaka-Gantenbein
Christina Kanaka-Gantenbein

30 September 2011 in Pediatric Neurology
Verified
Journal Article
Closed access
FTFlora Tzifi
Flora Tzifi
RPRoser Pons
Roser Pons
CACorina Athanassaki
Corina Athanassaki
MPMyrto Poulou
Myrto Poulou
EKEmmanuel Kanavakis
Emmanuel Kanavakis

1 January 2014 in Prague Medical Report
Verified
Journal Article
Open access
PDF file
FTFlora Tzifi
Flora Tzifi
PHPhilip Hawkins
Philip Hawkins
EAErato Atsali
Erato Atsali
DKDoxa Kotzia
Doxa Kotzia
AAAchilleas Attilakos
Achilleas Attilakos
Familial Mediterranean Fever (FMF) is a systemic auto-inflammatory disease characterized by recurrent episodes of fever accompanied by synovial, serosal and/or cutaneous inflammation. Liver involvement has been described mainly in patients with paired FMF gene mutations, i.e. involving both alleles, and rarely in patients heterozygous for FMF mutations. These patients may present with acute or chronic hepatitis, with or without liver failure. Non-alcoholic hepatitis, mild hyperbilirubinemia, and elevation of liver enzymes of unknown etiology should also raise suspicion of FMF. Patients with FMF and liver involvement usually respond to colchicine medication. The mutation I259V (c.775A<G) on exon 2 of the MEFV gene has not been reported in FMF patients with liver involvement. Furthermore, among several MEFV gene variants, it has been reported so far in only one heterozygous FMF patient of Turkish ancestry presenting with abdominal pain without any hepatic complication. Herein, the second case of a FMF patient heterozygous for the above mentioned mutation is discussed. It is a male child with FMF clinical phenotype which presented two consecutively episodes of acute hepatitis during fever attacks, that spontaneously resolved. Therapeutic trial with colchicine was successful, since no other fever attacks and acute hepatitis episodes were noticed.